



## COMPANY OVERVIEW

Exactus is a publicly traded life science company based in Richmond, Virginia that is developing for commercialization point-of-care (POC) diagnostics for measuring proteolytic enzymes in the blood. We anticipate our lead product, the FibrLyzer™, will provide a simple and affordable means to assess the fibrinolytic status of patients in a broad range of applications and that the use of the FibrLyzer™ could provide the basis for improved management of patients who are at-risk of hemorrhage, speeding treatment decisions and potentially improving patient outcomes and saving money.

Our second product candidate, the MatriLyzer™, may be used to detect the recurrence of cancer, and can be used as an at-home monitoring device or during routine office visits. The appearance of elevated levels of collagenase, the enzyme that degrades collagen, have been proven to be an early hallmark of cancer. The MatriLyzer™ is expected to communicate directly with the attending oncologist via a smart phone application to ensure that (i) the tests are being used properly and (ii) when collagenase levels are elevated signaling the need for the patient to have a more thorough examination.

### Exactus, Inc. to Present at MedTech Strategist Innovation Summit

Apr 20 2017, 4:00 PM EDT

### Exactus, Inc. to Present at BIO CEO & Investor Conference

Feb 8 2017, 8:00 AM EST

## STOCK OVERVIEW

<b>Symbol</b>	EXDI
<b>Exchange</b>	OTCQB
<b>Market Cap</b>	322.18k
<b>Last Price</b>	\$0.0081
<b>52-Week Range</b>	\$0.01 - \$0.30

12/14/2018 03:45 PM EST

## MANAGEMENT TEAM

### Philip J. Young

CEO and Chairman of the Board

### James R. Erickson, PhD.

Chief Business Officer

### Timothy J. Ryan

Executive Vice President

### Kelley A. Wendt

Chief Financial Officer

## EXACTUS, INC.

4870 Sadler Rd. Suite 300  
Glen Allen, VA 23060

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.